We serve Chemical Name:3-Oxo-N-(4-sulfamoylphenyl)butanamide CAS:4542-32-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Oxo-N-(4-sulfamoylphenyl)butanamide
CAS.NO:4542-32-9
Synonyms:N-acetoacetyl-sulfanilic acid amide;N-Acetoacetyl-sulfanilsaeure-amid;EINECS 224-892-8;p-Sufamoylacetacetanilid
Molecular Formula:C10H12N2O4S
Molecular Weight:256.27800
HS Code:2935009090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.411g/cm3
Index of Refraction:1.593
PSA:114.71000
Exact Mass:256.05200
LogP:2.10570
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-acetoacetyl-sulfanilic acid amide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-Sufamoylacetacetanilid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-Sufamoylacetacetanilid Use and application,N-acetoacetyl-sulfanilic acid amide technical grade,usp/ep/jp grade.
Related News: If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. 3-Oxo-N-(4-sulfamoylphenyl)butanamide manufacturer By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names. 3-Oxo-N-(4-sulfamoylphenyl)butanamide supplier If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said. 3-Oxo-N-(4-sulfamoylphenyl)butanamide vendor Advanced intermediate suppliers not only have strong bargaining power for junior suppliers, but more importantly, because they undertake the production of advanced intermediates with high technical content and maintain closer ties with multinational companies, raw materials Price fluctuations have little effect on it. 3-Oxo-N-(4-sulfamoylphenyl)butanamide factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.
